Related Experiment Video
Updated: Jun 9, 2026

Conducting Respiratory Oscillometry in an Outpatient Setting
Published on: April 8, 2022
A Prospective, Multicenter Study Investigating the Effectiveness of an Oscillating Positive Expiratory Pressure
Claude Poirier1, Pierre-Alexandre Ménard2, Romina Tate Gemelli3
1Department of Medicine, Centre Inspir'er, Montréal, Québec, Canada.
Rationale:
Clinical benefits of oscillating positive expiratory pressure (OPEP) devices have been previously demonstrated in many respiratory diseases, including chronic obstructive pulmonary disease (COPD). This study aimed to provide patient-reported outcomes of OPEP treatment in COPD patients in Québec, Canada.
Method:
Recruitment took place across 4 sites. Included patients had a COPD Assessment Test (CAT) score greater than 10 and a mucus score of 2 or greater. Aerobika∗ OPEP (TMI) devices were provided, with instructions on usage and technique. CAT assessments were collected at baseline and 6 and 12 weeks. At the final visit, patients were asked whether they would continue to use the device and provided ratings on usability and satisfaction.
Result:
Data were analyzed from 46 patients. The average CAT score at 6 weeks was significantly lower than baseline (19.02 ± 6.59 vs. 23.65 ± 6.44, p < 0.00001), with 31/44 patients (70.5%) reaching the minimum clinically important difference (MCID). Scores decreased further at 12 weeks (16.15 ± 6.06), a significant improvement from 6 weeks (p = 0.0052). MCID was reached by 39/44 patients (84.8%) after 12 weeks of treatment. Average 6 and 12 week mucus scores (2.59 ± 1.02 and 2.28 ± 1.13, respectively) were both significantly lower than baseline (3.63 ± 0.97; p < 0.00001 at 6 and 12 weeks). Regarding device feedback, 43/44 patients (97.7%) would continue using the device. The proportion of patients that provided 4/5 or 5/5 satisfaction ratings was 40/45 (88.9%), 43/45 (95.6%), and 40/45 (88.9%) for ease of use, quality, and overall satisfaction, respectively. No device-related adverse events were reported.
Conclusion:
Statistically significant clinical improvements were observed with OPEP therapy. This study supports the use of the Aerobika∗ OPEP in conjunction with standard of care in COPD patients to manage symptoms and enhance quality of life. Patient feedback shows high levels of acceptance and perceived value of the device.
More Related Videos
13:10Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique
Published on: May 15, 2013
04:53Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Published on: October 18, 2024
Related Concept Videos
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease I: Introduction
Chronic Obstructive Pulmonary Disease-I: Introduction